SCHEMBL28619993

SCHEMBL28619993

Nc1cccc(OC(=O)C2CC2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ KMT2A Q03164 6/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ ELANE P08246 2/20 0.49
▸ USP2 O75604 1/20 0.46
▸ MEN1 O00255 4/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ FABP7 O15540 2/20 0.42
▸ FABP5 Q01469 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ FABP3 P05413 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13292719 1.00 POLB (0.58) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL15092194 0.81 POLB (0.84) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL4120652 0.79 POLB (0.58) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL27779967 0.79 POLB (0.58) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL27947134 0.79 LMNA (0.61) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL23291730 0.79 POLB (0.58) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL17287375 0.79 POLB (0.58) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL4544899 0.79 LMNA (0.61) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL6689211 0.79 POLB (0.58) POLBL3MBTL1KMT2ASMN1; SMN2HTT
SCHEMBL13292722 0.78 KMT2A (0.68) POLBL3MBTL1KMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113348167-A (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer 奈可萨斯医药有限公司 2021-09-03 — — CN disclosed
Send feedback